SKYRIZI DIN 02532107
Health Canada record
| Active ingredient(s) | RISANKIZUMAB 60 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L04AC18 RIZANKIZUMAB |
| Original market date | 01-Dec-2022 |
| Current status date | 01-Dec-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
AbbVie Corporation — licence 101988, currently licensed, last inspection rating C (2023-07-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RISANKIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02519283 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 150 MG | Marketed |
| 02519291 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 150 MG | Marketed |
| 02532093 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 360 MG | Marketed |
| 02546922 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 90 MG | Approved |
| 02552507 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 180 MG | Marketed |
| 02487454 | SKYRIZI | ABBVIE CORPORATION | Solution | RISANKIZUMAB 75 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29238 | 2022-10-19 | Supplement to a New Drug Submission (SNDS) | New Indication & New Presentations : Skyrizi (risankizumab injection/ risankizumab for injection) is indicated for: the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, intolerance, or demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies |